The Pharmaletter

One To Watch

vaccentis_company

Vaccentis

A clinical-stage Swiss biopharmaceutical company developing patient-individualized medicines to improve patients’ chances of recovery from chronic and malignant diseases.

Vaccentis’ lead product VCC-001, which is in late-stage clinical development to treat non-metastatic renal cell carcinomas post nephrectomy. Vaccentis’ proprietary production methodology reduces complexity and allows for a three to four week vaccine delivery time, significantly shorter than normally seen with other personalized biologics.

Want to Update your Company's Profile?


More Vaccentis news >